Claudio Tripodo

List of Publications by Year
in descending order

182	9,707	36303 51	42399 92
papers	citations	h-index	g-index

186	186	186	15570
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Burkitt lymphoma with a granulomatous reaction: an M1/Th1â€polarised microenvironment is associated with controlled growth and spontaneous regression. Histopathology, 2022, 80, 430-442.	2.9	8
2	PDâ€1â€induced T cell exhaustion is controlled by a Drp1â€dependent mechanism. Molecular Oncology, 2022, 16, 188-205.	4.6	15
3	DNA damage response at telomeres boosts the transcription of SARSâ€CoVâ€2 receptor ACE2 during aging. EMBO Reports, 2022, 23, e53658.	4.5	24
4	Release of IFNÎ³ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells. Clinical Cancer Research, 2022, 28, 3141-3155.	7.0	20
5	Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation. ELife, 2022, 11, .	6.0	5
6	Definition of model-based control strategies for the Molten Salt Fast Reactor nuclear power plant. Nuclear Engineering and Design, 2021, 373, 111015.	1.7	6
7	A novel CXCR4 antagonist counteracts paradoxical generation of cisplatin-induced pro-metastatic niches in lung cancer. Molecular Therapy, 2021, 29, 2963-2978.	8.2	9
8	Conceptual design of the main Ancillary Systems of the ITER Water Cooled Lithium Lead Test Blanket System. Fusion Engineering and Design, 2021, 167, 112345.	1.9	11
9	Castration-Induced Downregulation of SPARC in Stromal Cells Drives Neuroendocrine Differentiation of Prostate Cancer. Cancer Research, 2021, 81, 4257-4274.	0.9	11
10	SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis. IScience, 2021, 24, 102510.	4.1	5
11	Papuloâ€purpuric dermatitis of childhood: a distinct PLEVAâ€like eruption associated to SARSâ€CoVâ€2 infection. Clinical, histopathological and immunohistochemical study of 10 cases. Pediatric Dermatology, 2021, 38, 1185-1190.	0.9	11
12	The prolyl-isomerase PIN1 is essential for nuclear Lamin-B structure and function and protects heterochromatin under mechanical stress. Cell Reports, 2021, 36, 109694.	6.4	15
13	Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. Cell, 2021, 184, 5230-5246.e22.	28.9	109
14	Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2021, 13, 4680.	3.7	6
15	Tuning gut microbiota through a probiotic blend in gemcitabineâ€treated pancreatic cancer xenografted mice. Clinical and Translational Medicine, 2021, 11, e580.	4.0	12
16	A tribute to Juan Rosai. Pathologica, 2021, 113, 302-304.	3.4	0
17	A Spatially Resolved Dark- versus Light-Zone Microenvironment Signature Subdivides Germinal Center-Related Aggressive B Cell Lymphomas. IScience, 2020, 23, 101562.	4.1	27
18	Hematopoietic stem cell function in Î²-thalassemia is impaired and is rescued by targeting the bone marrow niche. Blood, 2020, 136, 610-622.	1.4	23

#	Article	IF	Citations
19	Abstract 1106: Cisplatin-induced activation of SDF-1/CXCR4 axis sustains lung cancer metastasis by promoting co-recruitment of metastasis initiating cells and inflammatory monocytes. , 2020, , .		0
20	Development of a control-oriented power plant simulator for the molten salt fast reactor. EPJ Nuclear Sciences & Technologies, 2019, 5, 13.	0.7	5
21	Time for a â€œPlan Bâ€• in Peritoneal Metastatic Disease. Cancer Research, 2019, 79, 5-6.	0.9	10
22	Hematopoietic Stem Cell Function in Î²-Thalassemia Is Impaired and Is Rescued By Targeting the Bone Marrow Niche. Blood, 2019, 134, 967-967.	1.4	0
23	Abstract 4959: The gut microbiota contributes to the effectiveness of HER2-targeted therapy. , 2019, , .		0
24	Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer. Cancer Immunology Research, 2018, 6, 552-565.	3.4	44
25	Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence. Science Translational Medicine, 2018, 10, .	12.4	13
26	Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Science Translational Medicine, 2018, 10, .	12.4	187
27	Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat. Hematological Oncology, 2018, 36, 360-362.	1.7	15
28	IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis. OncoImmunology, 2018, 7, e1397249.	4.6	6
29	Real-time detection of BRAF V600E mutation from archival hairy cell leukemia FFPE tissue by nanopore sequencing. Molecular Biology Reports, 2018, 45, 1-7.	2.3	10
30	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. British Journal of Haematology, 2018, 183, 755-765.	2.5	41
31	Drp1 Controls Effective T Cell Immune-Surveillance by Regulating T Cell Migration, Proliferation, and cMyc-Dependent Metabolic Reprogramming. Cell Reports, 2018, 25, 3059-3073.e10.	6.4	82
32	Wnt3a Neutralization Enhances T-cell Responses through Indirect Mechanisms and Restrains Tumor Growth. Cancer Immunology Research, 2018, 6, 953-964.	3.4	25
33	Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer. Frontiers in Immunology, 2018, 9, 1748.	4.8	23
34	Abstract 4981: Circulating mir-320 promotes immunosuppressive macrophages M2 phenotype associated with lung cancer progression. , 2018, , .		0
35	Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation. , 2018, , .		0
36	Targeting a Specific Glycosylated Epitope of CD43 with a New Humanized Monoclonal Antibody for the Treatment of Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL). Blood, 2018, 132, 1418-1418.	1.4	1

#	Article	IF	Citations
37	Mast cells contribute to autoimmune diabetes by releasing interleukin-6 and failing to acquire a tolerogenic IL-10+ phenotype. Clinical Immunology, 2017, 178, 29-38.	3.2	19
38	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. Molecular Cancer Research, 2017, 15, 541-552.	3.4	24
39	Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments. Cancer Immunology, Immunotherapy, 2017, 66, 1059-1067.	4.2	36
40	Rheostatic Functions of Mast Cells in the Control of Innate and Adaptive Immune Responses. Trends in Immunology, 2017, 38, 648-656.	6.8	66
41	Reciprocal influence of B cells and tumor macro and microenvironments in theApc^{Min/+}model of colorectal cancer. OncoImmunology, 2017, 6, e1336593.	4.6	8
42	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. Cancer Research, 2017, 77, 3685-3699.	0.9	27
43	Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2017, 23, 5149-5161.	7.0	59
44	Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelialâ€“Stromal Tumors by Targeting PDGFR-Î². Molecular Cancer Therapeutics, 2017, 16, 365-375.	4.1	11
45	Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cells. Cancer Letters, 2017, 410, 201-211.	7.2	15
46	Distribution and function of the complement protein C1q in malignant pleural mesothelioma microenvironment. Molecular Immunology, 2017, 89, 121.	2.2	0
47	The good and bad of targeting cancer-associated extracellular matrix. Current Opinion in Pharmacology, 2017, 35, 75-82.	3.5	23
48	Antibodyâ€mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. FASEB Journal, 2017, 31, 5356-5370.	0.5	10
49	Mast cells are associated with the onset and progression of celiac disease. Journal of Allergy and Clinical Immunology, 2017, 139, 1266-1274.e1.	2.9	39
50	Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth. Frontiers in Immunology, 2017, 8, 1559.	4.8	44
51	Abstract 5437: miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple-negative breast cancer. , 2017, , .		0
52	Mesenchymal Transition of High-Grade Breast Carcinomas Depends on Extracellular Matrix Control of Myeloid Suppressor Cell Activity. Cell Reports, 2016, 17, 233-248.	6.4	84
53	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematology,the, 2016, 3, e467-e479.	4.6	63
54	miR-9 and miR-200 Regulate PDGFRÎ²-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. Cancer Research, 2016, 76, 5562-5572.	0.9	74

#	Article	IF	Citations
55	A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. Nano Research, 2016, 9, 537-548.	10.4	17
56	MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. Journal of Hepatology, 2016, 64, 682-690.	3.7	106
57	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nature Communications, 2016, 7, 10346.	12.8	224
58	Arginase 1 Is a Marker of Myeloid-Mediated Immunosuppression with Prognostic Meaning in Classic Hodgkin Lymphoma. Blood, 2016, 128, 1770-1770.	1.4	1
59	The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. Oncotarget, 2016, 7, 67333-67346.	1.8	27
60	Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget, 2016, 7, 224-240.	1.8	33
61	Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget, 2016, 7, 3905-3920.	1.8	9
62	Abstract B157: OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. , 2016, , .		0
63	Abstract A18: miR-9 and miR-200 regulate PDGFRÎ²-mediated endothelial differentiation of neoplastic cells in triple-negative breast cancer. , 2016, , .		0
64	Abstract 3289: Microenvironment modulation and enhancement of cytotoxic therapy by the heparanase inhibitor Roneparstat against human B-non Hodgkin lymphomas. , 2016, , .		0
65	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. Blood, 2015, 125, 1768-1771.	1.4	40
66	Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies. International Journal of Nanomedicine, 2015, 10, 4099.	6.7	26
67	IFI16Expression Is Related to Selected Transcription Factors during B-Cell Differentiation. Journal of Immunology Research, 2015, 2015, 1-20.	2.2	18
68	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 193-200.	3.6	28
69	Mast Cells Infiltrating Inflamed or Transformed Gut Alternatively Sustain Mucosal Healing or Tumor Growth. Cancer Research, 2015, 75, 3760-3770.	0.9	27
70	The ins and outs of osteopontin. OncoImmunology, 2015, 4, e978711.	4.6	3
71	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. Leukemia and Lymphoma, 2015, 56, 3281-3287.	1.3	25
72	SOCS2 Controls Proliferation and Stemness of Hematopoietic Cells under Stress Conditions and Its Deregulation Marks Unfavorable Acute Leukemias. Cancer Research, 2015, 75, 2387-2399.	0.9	39

#	Article	IF	Citations
73	SCD5â€induced oleic acid production reduces melanoma malignancy by intracellular retention of SPARC and cathepsin B. Journal of Pathology, 2015, 236, 315-325.	4.5	34
74	RORC1 Regulates Tumor-Promoting â€œEmergencyâ€•Granulo-Monocytopoiesis. Cancer Cell, 2015, 28, 253-269.	16.8	154
75	Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. OncoImmunology, 2015, 4, e1030560.	4.6	21
76	Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment. OncoImmunology, 2015, 4, e1040214.	4.6	37
77	Mast Cells Boost Myeloid-Derived Suppressor Cell Activity and Contribute to the Development of Tumor-Favoring Microenvironment. Cancer Immunology Research, 2015, 3, 85-95.	3.4	59
78	Alteration of HSC Functions in Thalassemia. Blood, 2015, 126, 4752-4752.	1.4	2
79	A ceRNA approach may unveil unexpected contributors to deletion syndromes, the model of 5q-syndrome. Oncoscience, 2015, 2, 872-879.	2.2	9
80	OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.. Journal of Clinical Oncology, 2015, 33, e16576-e16576.	1.6	0
81	Abstract 4054: Mast cells contribute to T cell tolerance against prostate cancer- associated antigens favoring tumor growth. , 2015, , .		0
82	MEF2C and SOCS2 in stemness regulation. Oncoscience, 2015, 2, 936-937.	2.2	2
83	Microenvironment Regulation of IL23R/IL-23 Axis Drives Chronic Lymphocytic Leukemia (CLL) Progression. Blood, 2015, 126, 616-616.	1.4	1
84	Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies. OncoImmunology, 2014, 3, e28989.	4.6	34
85	Defective Stromal Remodeling and Neutrophil Extracellular Traps in Lymphoid Tissues Favor the Transition from Autoimmunity to Lymphoma. Cancer Discovery, 2014, 4, 110-129.	9.4	100
86	C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4209-4214.	7.1	140
87	Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Modern Pathology, 2014, 27, 814-822.	5.5	48
88	Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus. Frontiers in Microbiology, 2014, 5, 728.	3.5	37
89	Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology, 2014, 60, 1494-1507.	7.3	70
90	Osteopontin Shapes Immunosuppression in the Metastatic Niche. Cancer Research, 2014, 74, 4706-4719.	0.9	110

#	Article	IF	Citations
91	Mast Cells Control the Expansion and Differentiation of IL-10â€“Competent B Cells. Journal of Immunology, 2014, 193, 4568-4579.	0.8	33
92	PDGFRÎ² and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells. Molecular Oncology, 2014, 8, 968-981.	4.6	37
93	Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica, 2014, 99, 1078-1087.	3.5	43
94	Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood, 2014, 123, 1836-1849.	1.4	37
95	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
96	Abstract 2362: Identification and characterization of pathogenetic pathways and potential therapeutic targets in tumors derived from histiocytes and follicular dendritic cells. , 2014, , .		0
97	Abstract A42: miR34a: A valuable indicator of differential outcome of Ewing sarcoma patients with complex functions. , 2014, , .		0
98	The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miRâ€221&222â€câ€FOS pathway. International Journal of Cancer, 2013, 133, 879-892.	5.1	55
99	Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer. Cancer Immunology, Immunotherapy, 2013, 62, 1811-1819.	4.2	3
100	Response to Villanacci et al.. American Journal of Gastroenterology, 2013, 108, 620.	0.4	2
101	Class IIa HDACs repressive activities on MEF2â€dependent transcription are associated with poor prognosis of ER ⁺ breast tumors. FASEB Journal, 2013, 27, 942-954.	0.5	41
102	The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica, 2013, 98, 1115-1123.	3.5	92
103	RNA recognition by human TLR8 can lead to autoimmune inflammation. Journal of Experimental Medicine, 2013, 210, 2903-2919.	8.5	167
104	New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. PLoS ONE, 2013, 8, e74216.	2.5	34
105	Liver Follicular Helper T-Cells Predict the Achievement of Virological Response following Interferon-Based Treatment in HCV-Infected Patients. Antiviral Therapy, 2012, 17, 111-118.	1.0	12
106	The Aryl Hydrocarbon Receptor Modulates Acute and Late Mast Cell Responses. Journal of Immunology, 2012, 189, 120-127.	0.8	70
107	Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas. Advances in Hematology, 2012, 2012, 1-12.	1.0	15
108	Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood, 2012, 120, 3541-3554.	1.4	44

#	Article	IF	Citations
109	Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood, 2012, 120, 3007-3018.	1.4	350
110	Sistemic calciphylaxis and thrombotic microangiopathy in a kidney transplant patient: Two mixing fatal syndromes?. Medical Hypotheses, 2012, 79, 74-75.	1.5	9
111	Mesenchymal stem cells display hepato-protective activity in lymphoma bearing xenografts. Investigational New Drugs, 2012, 30, 803-807.	2.6	4
112	A complex case of fatal calciphylaxis in a female patient with hyperparathyroidism secondary to end stage renal disease of graft and coexistence of haemolytic uremic syndrome. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 262-265.	0.6	9
113	Abstract 2997: Peripheral T-cell lymphomas not otherwise specified correspond to distinct mature T-cell populations basing on the global gene expression profile. , 2012, , .		0
114	New Therapeutic Approach for the Treatment of B-Cell Disorders Using Chlorambucil/Hydroxychloroquine-Loaded AntiCD20 Nanoparticles. Blood, 2012, 120, 158-158.	1.4	0
115	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Digestive and Liver Disease, 2011, 43, 404-410.	0.9	27
116	Pathobiology of Hodgkin Lymphoma. Advances in Hematology, 2011, 2011, 1-18.	1.0	46
117	SPARC Oppositely Regulates Inflammation and Fibrosis in Bleomycin-Induced Lung Damage. American Journal of Pathology, 2011, 179, 3000-3010.	3.8	62
118	The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. Journal of Autoimmunity, 2011, 37, 300-310.	6.5	29
119	MMP-13 stimulates osteoclast differentiation and activation in tumour breast bone metastases. Breast Cancer Research, 2011, 13, R105.	5.0	92
120	SNPs Array Karyotyping Reveals a Novel Recurrent 20p13 Amplification in Primary Myelofibrosis. PLoS ONE, 2011, 6, e27560.	2.5	5
121	How I diagnose and treat splenic lymphomas. Blood, 2011, 117, 2585-2595.	1.4	91
122	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 2011, 117, 1595-1604.	1.4	173
123	Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes. Blood, 2011, 117, 3596-3608.	1.4	128
124	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood, 2011, 118, 6353-6361.	1.4	45
125	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood, 2011, 118, 4421-4430.	1.4	30
126	CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood, 2011, 118, 6141-6152.	1.4	122

#	Article	IF	Citations
127	A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. British Journal of Haematology, 2011, 152, 284-294.	2.5	28
128	Exacerbated experimental autoimmune encephalomyelitis in mast-cell-deficient KitW-sh/W-sh mice. Laboratory Investigation, 2011, 91, 627-641.	3.7	61
129	Peripheral T-cell lymphoma classification: the matter of cellular derivation. Expert Review of Hematology, 2011, 4, 415-425.	2.2	30
130	The bone marrow stroma in hematological neoplasmsâ€"a guilty bystander. Nature Reviews Clinical Oncology, 2011, 8, 456-466.	27.6	42
131	Technical Advance: Soluble OX40 molecule mimics regulatory T cell modulatory activity on FcÉ›RI-dependent mast cell degranulation. Journal of Leukocyte Biology, 2011, 90, 831-838.	3.3	12
132	Mast Cell Targeting Hampers Prostate Adenocarcinoma Development but Promotes the Occurrence of Highly Malignant Neuroendocrine Cancers. Cancer Research, 2011, 71, 5987-5997.	0.9	124
133	CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells. Blood, 2011, 118, 621-621.	1.4	0
134	Mast cells enhance proliferation of B lymphocytes and drive their differentiation toward IgA-secreting plasma cells. Blood, 2010, 115, 2810-2817.	1.4	113
135	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood, 2010, 116, 584-592.	1.4	51
136	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 2010, 51, 1158-1167.	7.3	371
137	A nonâ€redundant role for OX40 in the competitive fitness of Treg in response to ILâ€2. European Journal of Immunology, 2010, 40, 2902-2913.	2.9	62
138	Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38⁺CD49d⁺ chronic lymphocytic leukaemia cells. British Journal of Haematology, 2010, 150, 111-112.	2.5	33
139	Oncogene-Driven Intrinsic Inflammation Induces Leukocyte Production of Tumor Necrosis Factor That Critically Contributes to Mammary Carcinogenesis. Cancer Research, 2010, 70, 7764-7775.	0.9	31
140	T Cell Large Granular Lymphocytic Leukemia in Association with SjÃ¶grenâ€™s Syndrome. Acta Haematologica, 2010, 124, 5-8.	1.4	7
141	Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. Journal of Experimental Medicine, 2010, 207, 2931-2942.	8.5	175
142	Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Expert Opinion on Biological Therapy, 2010, 10, 863-873.	3.1	16
143	An Alternative Role of C1q in Cell Migration and Tissue Remodeling: Contribution to Trophoblast Invasion and Placental Development. Journal of Immunology, 2010, 185, 4420-4429.	0.8	135
144	Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma. Current Clinical Pharmacology, 2010, 5, 246-250.	0.6	6

#	Article	IF	Citations
145	Exploring a regulatory role for mast cells: â€˜MCregsâ€™?. Trends in Immunology, 2010, 31, 97-102.	6.8	62
146	Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma. American Journal of Pathology, 2010, 177, 792-802.	3.8	82
147	Human Bone Marrow Mesenchymal Stem Cells Display Anti-Cancer Activity in SCID Mice Bearing Disseminated Non-Hodgkin's Lymphoma Xenografts. PLoS ONE, 2010, 5, e11140.	2.5	128
148	Gene Expression Analysis Uncovers Similarity and Differences Among Burkitt Lymphoma Subtypes. Blood, 2010, 116, 2494-2494.	1.4	2
149	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. Cancer Research, 2009, 69, 4001-4009.	0.9	153
150	Overexpression of interleukinâ€23, but not interleukinâ€17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 60, 955-965.	6.7	215
151	Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Preâ€“Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial. Clinical Lymphoma and Myeloma, 2009, 9, 138-144.	1.4	9
152	Gamma-delta T-cell lymphomas. Nature Reviews Clinical Oncology, 2009, 6, 707-717.	27.6	152
153	Progressive visceral leishmaniasis misdiagnosed as cirrhosis of the liver: a case report. Journal of Medical Case Reports, 2009, 3, 7265.	0.8	5
154	CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis. Haematologica, 2009, 94, 127-130.	3.5	33
155	C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. Blood, 2009, 113, 3640-3648.	1.4	44
156	Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood, 2009, 114, 2639-2648.	1.4	184
157	An automated image analysis methodology for classifying megakaryocytes in chronic myeloproliferative disorders. Medical Image Analysis, 2008, 12, 703-712.	11.6	35
158	Angioimmunoblastic T-cell lymphoma. Critical Reviews in Oncology/Hematology, 2008, 68, 264-271.	4.4	64
159	Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Molecular Immunology, 2008, 45, 2629-2640.	2.2	82
160	Is local complement activation involved in renal damage in patients with atypical haemolytic uraemic syndrome?. Molecular Immunology, 2008, 45, 4101-4102.	2.2	1
161	CD4+CD25+ Regulatory T Cells Suppress Mast Cell Degranulation and Allergic Responses through OX40-OX40L Interaction. Immunity, 2008, 29, 771-781.	14.3	333
162	The soluble terminal complement complex (SC5b-9) up-regulates osteoprotegerin expression and release by endothelial cells: implications in rheumatoid arthritis. Rheumatology, 2008, 48, 293-298.	1.9	29

#	Article	IF	Citations
163	An Update on the Xenograft and Mouse Models Suitable for Investigating New Therapeutic Compounds for the Treatment of B-Cell Malignancies. Current Pharmaceutical Design, 2008, 14, 2023-2039.	1.9	20
164	In Vivo Biodistribution and Lifetime Analysis of Cy5.5-Conjugated Rituximab in Mice Bearing Lymphoid Tumor Xenograft Using Time-Domain Near-Infrared Optical Imaging. Molecular Imaging, 2008, 7, 7290.2008.00028.	1.4	29
165	Associations between Notch-2, Akt-1 and HER2/neu Expression in Invasive Human Breast Cancer: A Tissue Microarray Immunophenotypic Analysis on 98 Patients. Pathobiology, 2007, 74, 317-322.	3.8	22
166	In vivoTargeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab. Cancer Research, 2007, 67, 10556-10563.	0.9	141
167	Constant Detection of Cyclooxygenase 2 in Terminal Stages of Myeloid Maturation. Acta Haematologica, 2007, 117, 48-50.	1.4	5
168	Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4. Cell Stem Cell, 2007, 1, 389-402.	11.1	968
169	Release of naltrexone on buccal mucosa: Permeation studies, histological aspects and matrix system design. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 425-433.	4.3	78
170	Use of intrapleural bortezomib in myelomatous pleural effusion. British Journal of Haematology, 2007, 139, 621-622.	2.5	22
171	Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood, 2006, 107, 4643-4649.	1.4	217
172	Small Bowel Angiodysplasia Associated with von Willebrand's Disease: Report of a Case. Surgery Today, 2006, 36, 659-662.	1.5	1
173	Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. European Journal of Haematology, 2006, 76, 134-140.	2.2	14
174	Reply to Pich et al.: intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study. European Journal of Haematology, 2006, 77, 360-360.	2.2	0
175	Thyroid Sarcoidosis as a Unique Localization. Thyroid, 2006, 16, 1175.	4.5	13
176	Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. European Journal of Haematology, 2005, 75, 130-135.	2.2	25
177	Re: ?Splenic marginal zone B-cell lymphoma associated with primary Sjï¿½gren?s syndrome?. Clinical Rheumatology, 2005, 24, 187-187.	2.2	0
178	Identification of CD162 in plasma-cell dyscrasia. Lancet Oncology, The, 2005, 6, 632.	10.7	14
179	Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: Possible role in tumor promotion and angiogenesis. World Journal of Gastroenterology, 2005, 11, 4638.	3.3	54
180	Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment. The Hematology Journal, 2004, 5, 530-533.	1.4	20

#	Article	IF	Citations
181	Bone marrow biopsy in Hodgkin's lymphoma. European Journal of Haematology, 2004, 73, 149-155.	2.2	30
182	Splenic marginal zone lymphoma with or without villous lymphocytes. Cancer, 2004, 101, 2050-2057.	4.1	67